We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
NPS Pharma plans to make Natpara available for some patients with hypoparathyroidism in the second quarter of this year, following FDA approval late Friday. Read More
Pharmacists will only notify prescribers that they’ve switched a patient from brand to biosimilar if no database is available to make note of a swap. Read More
UK healthcare cost watchdogs confirmed Friday that Bayer’s Xarelto is cost-effective for preventing blood clots in patients who have had heart attacks. Read More
Baxter plans to roll out two of its Phoxillum solutions for continuous renal replacement therapy in the second quarter of this year, following FDA approval earlier this month. Read More
The FDA will maintain its policy on determining when an orphan drug product is entitled to market exclusivity, saying a recent federal court ruling that overruled the agency’s policy applied to just one drug and established no precedent. Read More
Hospira has submitted a BLA for anemia drug Retacrit, a proposed biosimilar to Amgen’s Epogen and Janssen’s Procrit — making it the fourth company to announce submission of a biosimilar application to the FDA. Read More